Table 1.
Clinical characteristics of patients with NonSqNSCLC stratified by fusion testing results.
| Clinical characteristics | Orthogonal testing performed (N = 3959) | FMI DNA CGP−/Orthog− (N = 3564) | FMI DNA CGP−/Orthog+ (N = 54) | FMI DNA CGP+/Orthog− (N = 148) | FMI DNA CGP+/Orthog+ (N = 193) |
|---|---|---|---|---|---|
| Age at 1L start (years), Median (IQR) | 65.9 (10.6) | 66.7 (10.2) | 64.0 (9.99) | 61.2 (11.5) | 56.1 (12.6) |
| Sex, n (%) | |||||
| Female | 2237 (56.5%) | 2017 (56.6%) | 29 (53.7%) | 88 (59.5%) | 103 (53.4%) |
| Male | 1722 (43.5%) | 1547 (43.4%) | 25 (46.3%) | 60 (40.5%) | 90 (46.6%) |
| Self-reported race, n (%) | |||||
| Asian | 163 (4.1%) | 143 (4.0%) | 1 (1.9%) | 3 (2.0%) | 16 (8.3%) |
| Black or African American | 257 (6.5%) | 233 (6.5%) | 2 (3.7%) | 10 (6.8%) | 12 (6.2%) |
| Hispanic or Latino | 5 (0.1%) | 5 (0.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Other race | 583 (14.7%) | 525 (14.7%) | 4 (7.4%) | 24 (16.2%) | 30 (15.5%) |
| White | 2687 (67.9%) | 2414 (67.7%) | 43 (79.6%) | 100 (67.6%) | 130 (67.4%) |
| Unknown/not documented | 264 (6.7%) | 244 (6.9%) | 4 (7.4%) | 11 (7.4%) | 5 (2.6%) |
| AJCC stage at diagnosis, n (%) | |||||
| I | 355 (9.0%) | 339 (9.5%) | 2 (3.7%) | 7 (4.7%) | 7 (3.6%) |
| II | 238 (6.0%) | 225 (6.3%) | 4 (7.4%) | 3 (2.0%) | 6 (3.1%) |
| III | 694 (17.5%) | 635 (17.8%) | 11 (20.4%) | 24 (16.2%) | 24 (12.4%) |
| IV | 2598 (65.6%) | 2296 (64.4%) | 36 (66.7%) | 112 (75.7%) | 154 (79.8%) |
| Other/unknown/not documented | 74 (1.9%) | 69 (1.9%) | 1 (1.9%) | 2 (1.4%) | 2 (1.0%) |
| Smoking history, n (%) | |||||
| History of smoking | 2958 (74.7%) | 2789 (78.3%) | 40 (74.1%) | 59 (39.9%) | 70 (36.3%) |
| No history of smoking | 998 (25.2%) | 772 (21.7%) | 14 (25.9%) | 89 (60.1%) | 123 (63.7%) |
| Unknown/not documented | 3 (0.1%) | 3 (0.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Practice type, n (%) | |||||
| Academic | 534 (13.5%) | 451 (12.7%) | 9 (16.7%) | 30 (20.3%) | 44 (22.8%) |
| Academic/community | 372 (9.4%) | 326 (9.2%) | 10 (18.5%) | 13 (8.8%) | 23 (11.9%) |
| Community | 3053 (77.1%) | 2787 (78.2%) | 35 (64.8%) | 105 (70.9%) | 126 (65.3%) |
| Socioeconomic status (SES), n (%) | |||||
| 1—Lowest SES | 472 (11.9%) | 433 (12.1%) | 10 (18.5%) | 13 (8.8%) | 16 (8.3%) |
| 2 | 647 (16.3%) | 598 (16.8%) | 7 (13.0%) | 17 (11.5%) | 25 (13.0%) |
| 3 | 818 (20.7%) | 724 (20.3%) | 6 (11.1%) | 42 (28.4%) | 46 (23.8%) |
| 4 | 886 (22.4%) | 805 (22.6%) | 16 (29.6%) | 24 (16.2%) | 41 (21.2%) |
| 5—Highest SES | 850 (21.5%) | 750 (21.0%) | 12 (22.2%) | 36 (24.3%) | 52 (26.9%) |
| Unknown | 286 (7.2%) | 254 (7.1%) | 3 (5.6%) | 16 (10.8%) | 13 (6.7%) |
| ECOG PS at 1L start, n (%) | |||||
| 0 | 1265 (32.0%) | 1121 (31.5%) | 19 (35.2%) | 53 (35.8%) | 72 (37.3%) |
| 1 | 1654 (41.8%) | 1506 (42.3%) | 27 (50.0%) | 57 (38.5%) | 64 (33.2%) |
| 2 | 369 (9.3%) | 345 (9.7%) | 3 (5.6%) | 10 (6.8%) | 11 (5.7%) |
| 3 | 84 (2.1%) | 78 (2.2%) | 0 (0.0%) | 2 (1.4%) | 4 (2.0%) |
| Unknown | 587 (14.8%) | 514 (14.4%) | 5 (9.3%) | 26 (17.6%) | 42 (21.8%) |
| 1L therapy class, n (%) | |||||
| No TKI Received | 3761 (95.0%) | 3551 (99.6%) | 40 (74.1%) | 101 (68.2%) | 69 (35.8%) |
| Received TKI | 198 (5.0%) | 13 (0.4%) | 14 (25.9%) | 47 (31.8%) | 124 (64.2%) |